| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1590 | 2018 |
| Statements from the Taormina expert meeting on occult hepatitis B virus infection G Raimondo, JP Allain, MR Brunetto, MA Buendia, DS Chen, M Colombo, ... Journal of hepatology 49 (4), 652-657, 2008 | 1158 | 2008 |
| Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases B Coco, F Oliveri, AM Maina, P Ciccorossi, R Sacco, P Colombatto, ... Journal of viral hepatitis 14 (5), 360-369, 2007 | 820 | 2007 |
| EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B: 13–14 September, 2002 Geneva, Switzerland Consensus statement (Long version) TE Jury Journal of Hepatology 39, 3-25, 2003 | 712 | 2003 |
| Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B MR Brunetto, F Moriconi, F Bonino, GKK Lau, P Farci, C Yurdaydin, ... Hepatology 49 (4), 1141-1150, 2009 | 668 | 2009 |
| Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein S Crotta, A Stilla, A Wack, A D'Andrea, S Nuti, U D'Oro, M Mosca, ... The Journal of experimental medicine 195 (1), 35-42, 2002 | 621 | 2002 |
| Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers MR Brunetto, F Oliveri, P Colombatto, F Moriconi, P Ciccorossi, B Coco, ... Gastroenterology 139 (2), 483-490, 2010 | 580 | 2010 |
| Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage C Dunn, M Brunetto, G Reynolds, T Christophides, PT Kennedy, ... The Journal of experimental medicine 204 (3), 667-680, 2007 | 536 | 2007 |
| Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study MR Brunetto, F Oliveri, B Coco, G Leandro, P Colombatto, JM Gorin, ... Journal of hepatology 36 (2), 263-270, 2002 | 516 | 2002 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind … M Buti, E Gane, WK Seto, HLY Chan, WL Chuang, T Stepanova, AJ Hui, ... The lancet Gastroenterology & hepatology 1 (3), 196-206, 2016 | 512 | 2016 |
| Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. MR Brunetto, MM Giarin, F Oliveri, E Chiaberge, M Baldi, A Alfarano, ... Proceedings of the National Academy of Sciences 88 (10), 4186-4190, 1991 | 493 | 1991 |
| Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis X Liu, P Invernizzi, Y Lu, R Kosoy, Y Lu, I Bianchi, M Podda, C Xu, G Xie, ... Nature genetics 42 (8), 658-660, 2010 | 474 | 2010 |
| Update of the statements on biology and clinical impact of occult hepatitis B virus infection G Raimondo, S Locarnini, T Pollicino, M Levrero, F Zoulim, AS Lok, ... Journal of hepatology 71 (2), 397-408, 2019 | 456 | 2019 |
| Hepatitis B surface antigen quantification: why and how to use it in 2011–a core group report HLY Chan, A Thompson, M Martinot-Peignoux, T Piratvisuth, M Cornberg, ... Journal of hepatology 55 (5), 1121-1131, 2011 | 447 | 2011 |
| T-lymphocyte response to hepatitis C virus in different clinical courses of infection P Botarelli, MR Brunetto, MA Minutello, P Calvo, D Unutmaz, AJ Weiner, ... Gastroenterology 104 (2), 580-587, 1993 | 439 | 1993 |
| The role of quantitative hepatitis B surface antigen revisited M Cornberg, VWS Wong, S Locarnini, M Brunetto, HLA Janssen, ... Journal of hepatology 66 (2), 398-411, 2017 | 407 | 2017 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 406 | 2022 |
| 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection K Agarwal, M Brunetto, WK Seto, YS Lim, S Fung, P Marcellin, SH Ahn, ... Journal of hepatology 68 (4), 672-681, 2018 | 402 | 2018 |
| IL-10–producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection A Das, G Ellis, C Pallant, AR Lopes, P Khanna, D Peppa, A Chen, P Blair, ... The Journal of Immunology 189 (8), 3925-3935, 2012 | 397 | 2012 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 372 | 2020 |
